Setting

Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity

Published: 26 Oct 2020 | Report Code: 10247759 | Pages: 115

Asia Pacific pharmaceutical contract manufacturing market will grow by 7.6% annually with a total addressable market cap of $489.1 billion over 2020-2030 owing to the rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity. Highlighted with 38 tables and 53 figures, this 116-page report “Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country. Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Active Pharmaceutical Ingredients (API) • Branded API Manufacturing • Generic API Manufacturing Finished Dosage Formulations (FDF) • Solid Dosage • Oral Liquids • Parenteral/Injectables • Other FDFs Secondary Packaging Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Clinical Manufacturing • Commercial Manufacturing Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Sterile Products • Non-Sterile Products Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	29
2.4 Emerging Opportunities and Market Trends	32
2.5 Porter’s Fiver Forces Analysis	36
3 Segmentation of Asia Pacific Market by Category	41
3.1 Market Overview by Category	41
3.2 Pharmaceutical Industry	43
3.3 Biopharmaceutical Industry	44
4 Segmentation of Asia Pacific Market by Product	45
4.1 Market Overview by Product	45
4.2 Active Pharmaceutical Ingredients (API)	47
4.2.1 Branded API Manufacturing	48
4.2.2 Generic API Manufacturing	49
4.3 Finished Dosage Formulations (FDF)	50
4.3.1 Solid Dosage	52
4.3.2 Oral Liquids	53
4.3.3 Parenteral/Injectables	54
4.3.4 Other FDFs	55
4.4 Secondary Packaging	56
5 Segmentation of Asia Pacific Market by Phase	57
5.1 Market Overview by Phase	57
5.2 Clinical Manufacturing	59
5.3 Commercial Manufacturing	60
6 Segmentation of Asia Pacific Market by Type	61
6.1 Market Overview by Type	61
6.2 Sterile Products	63
6.3 Non-Sterile Products	64
7 Segmentation of Asia Pacific Market by Therapeutic Application	65
7.1 Market Overview by Therapeutic Application	65
7.2 Infectious Diseases	67
7.3 Oncology	68
7.4 Metabolic Disorders	69
7.5 Cardiovascular Disorders	70
7.6 Central Nervous System	71
7.7 Pulmonary Disorders	72
7.8 Gastrointestinal Disorders	73
7.9 Other Therapeutic Applications	74
8 Asia-Pacific Market 2019-2030 by Country	75
8.1 Overview of Asia-Pacific Market	75
8.2 Japan	78
8.3 China	81
8.4 Australia	84
8.5 India	86
8.6 South Korea	88
8.7 Rest of APAC Region	90
9 Competitive Landscape	92
9.1 Overview of Key Vendors	92
9.2 New Product Launch, Partnership, Investment, and M&A	95
9.3 Company Profiles	96
Aenova Group	96
Baxter BioPharma Solutions	98
Boehringer Ingelheim	99
Catalent Inc.	100
Famar S.A.	101
Hospira, Inc.	102
Jubilant Life Sciences Ltd.	103
Lonza Group	104
Patheon Inc.	105
Pfizer CentreSource	106
Recipharm AB	107
Vetter Pharma International GmbH	108
10 Investing in Asia Pacific Market: Risk Assessment and Management	109
10.1 Risk Evaluation of Asia Pacific Market	109
10.2 Critical Success Factors (CSFs)	112
Related Reports and Products	115
List Of Tables

Table 1.  Snapshot of Asia Pacific Pharmaceutical Contract Manufacturing Market, 2019-2030	18
Table 2. Growth Rate of World Real GDP, 2017-2021	22
Table 3.  Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical Contract Manufacturing Market	32
Table 4. Asia Pacific Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, $ bn	41
Table 5. Asia Pacific Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	45
Table 6. Asia Pacific Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn	47
Table 7. Asia Pacific Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn	51
Table 8. Asia Pacific Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	57
Table 9. Asia Pacific Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, $ bn	61
Table 10. Asia Pacific Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	65
Table 11. APAC Pharmaceutical Contract Manufacturing Market by Country, 2019-2030, $ bn	76
Table 12. Japan Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	80
Table 13. Japan Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	80
Table 14. Japan Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	80
Table 15. China Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	83
Table 16. China Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	83
Table 17. China Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	83
Table 18. Australia Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	85
Table 19. Australia Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	85
Table 20. Australia Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	85
Table 21. India Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	87
Table 22. India Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	87
Table 23. India Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	87
Table 24. South Korea Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn	89
Table 25. South Korea Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn	89
Table 26. South Korea Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn	89
Table 27. Pharmaceutical Contract Manufacturing Market in Rest of APAC by Country, 2019-2030, $ bn	91
Table 28. Aenova Group: Company Snapshot	96
Table 29. Aenova Group: Business Segmentation	96
Table 30. Aenova Group: Product Portfolio	97
Table 31. Aenova Group: Revenue, 2016-2018, $ bn	97
Table 32. Aenova Group: Recent Developments	97
Table 33.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030	110
Table 34. Critical Success Factors and Key Takeaways	113
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Asia Pacific Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn	20
Figure 6. Impact of COVID-19 on Business	24
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market	26
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market	29
Figure 9. Investment Opportunity Analysis	33
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market	36
Figure 11. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue	42
Figure 12. Asia Pacific Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)	42
Figure 13. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, $ bn	43
Figure 14. Asia Pacific Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, $ bn	44
Figure 15. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue	46
Figure 16. Asia Pacific Addressable Market Cap in 2020-2030 by Product, Value ($ bn) and Share (%)	46
Figure 17. Asia Pacific Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn	47
Figure 18. Asia Pacific Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, $ bn	48
Figure 19. Asia Pacific Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, $ bn	49
Figure 20. Asia Pacific Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn	50
Figure 21. Asia Pacific Pharmaceutical Contract Manufacturing Market: Solid Dosage, 2019-2030, $ bn	52
Figure 22. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, $ bn	53
Figure 23. Asia Pacific Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, $ bn	54
Figure 24. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, $ bn	55
Figure 25. Asia Pacific Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, $ bn	56
Figure 26. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue	58
Figure 27. Asia Pacific Addressable Market Cap in 2020-2030 by Phase, Value ($ bn) and Share (%)	58
Figure 28. Asia Pacific Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, $ bn	59
Figure 29. Asia Pacific Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, $ bn	60
Figure 30. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue	62
Figure 31. Asia Pacific Addressable Market Cap in 2020-2030 by Type, Value ($ bn) and Share (%)	62
Figure 32. Asia Pacific Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, $ bn	63
Figure 33. Asia Pacific Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, $ bn	64
Figure 34. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue	66
Figure 35. Asia Pacific Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)	66
Figure 36. Asia Pacific Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, $ bn	67
Figure 37. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, $ bn	68
Figure 38. Asia Pacific Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, $ bn	69
Figure 39. Asia Pacific Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, $ bn	70
Figure 40. Asia Pacific Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, $ bn	71
Figure 41. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, $ bn	72
Figure 42. Asia Pacific Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, $ bn	73
Figure 43. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, $ bn	74
Figure 44. Breakdown of APAC Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue	76
Figure 45. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	77
Figure 46.  Pharmaceutical Contract Manufacturing Market in Japan, 2019-2030, $ bn	79
Figure 47.  Pharmaceutical Contract Manufacturing Market in China, 2019-2030, $ bn	82
Figure 48.  Pharmaceutical Contract Manufacturing Market in Australia, 2019-2030, $ bn	84
Figure 49.  Pharmaceutical Contract Manufacturing Market in India, 2019-2030, $ bn	86
Figure 50.  Pharmaceutical Contract Manufacturing Market in South Korea, 2019-2030, $ bn	88
Figure 51.  Pharmaceutical Contract Manufacturing Market in Rest of APAC, 2019-2030, $ bn	90
Figure 52. Growth Stage of Asia Pacific Pharmaceutical Contract Manufacturing Industry over the Forecast Period	92

Key Players (this may not be a complete list and extra companies can be added upon request): 
Aenova Group	
Baxter BioPharma Solutions	
Boehringer Ingelheim	
Catalent Inc.	
Famar S.A.	
Hospira, Inc.	
Jubilant Life Sciences Ltd.	
Lonza Group	
Patheon Inc.	
Pfizer CentreSource	
Recipharm AB	
Vetter Pharma International GmbH